Oral decitabine reactivates expression of the methylated γ-globin gene in Papio anubis

American Journal of Hematology

Volumn 82, Issue 11, 2007, Pages 981-985

  Lavelle, Donald ^a,b   Chin, Janet ^a,b   Vaitkus, Kestis ^a,b   Redkar, Sanjeev ^c   Phiasivongsa, Pasit ^c   Tang, Chunlin ^c   Will, Roselle ^c   Hankewych, Maria ^a,b   Roxas, Bryan ^a,b   Singh, Mahipal ^a,b   Saunthararajah, Yogen ^b   DeSimone, Joseph ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c SuperGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DECITABINE MESYLATE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPSILON GLOBIN; GAMMA GLOBIN; GLOBIN; HEMOGLOBIN F; HISTONE; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BABOON; CLINICAL TRIAL; DEMETHYLATION; DNA METHYLATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PAPIO ANUBIS; PRIORITY JOURNAL; PROMOTER REGION; SICKLE CELL ANEMIA; TUMOR SUPPRESSOR GENE;

ADMINISTRATION, ORAL; ANIMALS; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; FETAL HEMOGLOBIN; GENE EXPRESSION REGULATION; GENE SILENCING; GLOBINS; PAPIO ANUBIS;

EID: 35548990205     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21020     Document Type: Article

References (32)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
2. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
3. Jones PA. Overview of cancer epigenetics. Semin Hematol 2005;42 (3, Suppl 2):S3-S8.
4. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2 (Suppl 1):S4-S11.
5. Pliml J, Sorm F. Synthesis of 2′-deoxy-D-ribofuranosyl-5- azacytosine. Coll Czech Chem Commun 1964;29:2576-2577.
6. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
7. Wijermans PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS: The experience with the DNA demethylating agent 5·aza·2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84 (Suppl 13):9-17.
8. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomerthylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640.
9. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol 2005;42 (3, Suppl 2):S17-S22.
10. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
11. DeSimone J, Heller P, Hall L, et al. 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982;67:4428-4431.
12. Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-2384.
13. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99:3905-3908.
14. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietoc differentiation in patients with sickle cell disease. Blood 2003;102:3856-3870.
15. Hackanson B, Robbel C, Wijermans P, et al. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: Review of cytogenetic and molecular studies. Ann Hematol 2005;84 (Suppl 13):32-38.
16. Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004;6:151-158.
17. Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004;24:1270-1278.
18. Driscoll JS, Marquez VE, Plowman J, et al. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 1991;34:3280-3284.
19. Yoo CB, Cheng JC, Jones PA. Zebularine: A new drug for epigenetic therapy. Biochem Soc Trans 2004;32:910-912.
20. Momparler RL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol 2005;42 (3, Suppl 2):9-16.
21. DeSimone J, Heller P, Molokie RE, et al. Tetrahydrouridine, cytidine analogues, and hemoglobin F. Am J Hematol 1985;18:283-288.
22. Neil GL, Moxley TE, Kuentzel SL, et al. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemia mice. Cancer Chem Rep 1975;59:459-465.
23. Engel GL, Farid NA, Faul MM, et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000;198:239-247.
24. Badawy SI. Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. Int J Pharm 2000;223:81-87.
25. Lavelle D, Vaitkus K, Hankewych M, et al. Effect of 5-aza-2′- deoxycytidine on DNA methylation and covalent histone modifications associated with the ε-, γ-, and β-globin gene promoters in Papio anubis. Exp Hematol 2006;34:339-347.
26. DeSimone J, Schroeder WA, Shelton JB, et al. Detection of an epsilon gene in baboons after treatment with 5-azacytidine. Hemoglobin 1985;9:217-226.
27. Yue L, Saikawa Y, Ota K, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogen 2003;13:29-38.
28. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12:1794-1803.
29. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 2007;25:32-42.
30. Singer K, Chernoff AL, Singer L. Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. Blood 1951;6:413-420.
31. Raizis AM, Schmitt F, Jost J-P. A bisulfite method of 5-methylcytosine mapping that minimizes template degradation. Anal Biochem 1995;226:161-166.
32. Im H, Grass JA, Johnson KD, et al. Measurement of protein-DNA interactions in vivo by chromatin immunoprcipitation. Meth Mol Biol 2004;284:129-146.